November 18, 2016
Otsuka Pharmaceutical Co., Ltd.
New 1 mg Tablet Dosage of Antipsychotic ABILIFY Available in Japan
- An additional tablet dosage of the antipsychotic ABILIFY will be released in Japan on November 29.
- This will be the starting dosage for the indication of irritability associated with pediatric autistic spectrum that was obtained in September 2016.
- Three Japanese medical societies earlier indicated a pressing need for medications to better treat pediatric autism, and the MHLW (Ministry of Health, Labour and Welfare) requested that Otsuka commence development.
Otsuka Pharmaceutical Co., Ltd. will be released in Japan the additional 1 mg tablet dosage of the antipsychotic ABILIFY (generic name: aripiprazole) on November 29 2016. In September, ABILIFY obtained the indication of irritability associated with pediatric autistic spectrum. The 1 mg dosage is the starting dosage.
ABILIFY received approval from the U.S. FDA in 2009 for use in pediatric patients with irritability associated with autism disorders.
Information in this news release was current as of the original release date.